Zapping the brain to reset mood and metabolism?
NCT ID NCT05117983
Running, but no longer taking on new participants.
First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time
Summary
This trial tests whether repetitive transcranial magnetic stimulation (rTMS) can improve both depression and related metabolic issues like insulin resistance. About 90 adults with major depression or bipolar disorder will receive rTMS to a brain area involved in mood and reward. Researchers will measure changes in mood, brain activity, and metabolic markers over three months to see if this approach could offer a new way to treat depression with metabolic complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Repetitive transcranial magnetic stimulation (rTMS) to the left dorsolateral prefrontal cortex
- What this could lead to
- If it works, this could lead to a personalized, non-invasive brain stimulation treatment for depression that also improves metabolic health.
- What could go wrong
- This is an early-stage trial with a modest number of participants, so results may not apply broadly. rTMS is generally safe but can cause scalp discomfort or headaches.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 90 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2021
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * (1)Signed informed consent by patient or legal representative; * (2) male or female patient aged ≧20 and ≦70 years; * (3) a diagnosis of MDD or BD according to DSM criteria made by a specialist in psychiatry; * (4) a total score of at least 18 in the Hamilton Rating Scale for Depression (HDRS) at the screening stage; * (5) patient or a reliable caregiver can be expected to ensure acceptable compliance and visit attendance for the duration of the study. Exclusion Criteria: * (1) women of childbearing potential, not using adequate contraception as per investigator judgment or not willing to comply with contraception for the duration of the study; * (2) females who are pregnant or breast-feeding; * (3) other major DSM 5 diagnoses other than mood disorders, except for tobacco use disorder and anxiety disorder; * (4) current evidence of an uncontrolled and/or clinically significant medical condition, e.g. patients with extensive area of ischemic bruise, multiple sclerosis, cardiac, hepatic and renal failure that would compromise patient safety or preclude study participation; * (5) history of seizure or epilepsy; * (6) history of neurological diseases or traumatic brain injury; * (7) history of brain lesion, having received neurosurgery, meningitis or encephalitis; * (8) exacerbation of symptom severity, presenting severe suicidal ideation or self harm behavior during the screen or study period; * (9) presence of devices, e.g. pacemakers, cochlear prosthesis, neuro-stimulators, magnetic cochlear prosthesis, intracranial/intraocular metallic fragments; * (10) patient has received electroconvulsive therapy (ECT) within 3 months prior to the first intervention of the treatment; * (11) skin lesion at local site receiving rTMS stimulation; * (12) those who cannot tolerate the side effects or ever developed sleep disorder while receiving rTMS therapy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cheng-Kung University
Tainan, 704, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smartphone app bridge the mental health care gap?
- Can a smartphone program ease anxiety and depression in people with disabilities?
- Can a school program turn the tide on teen suicide?
- Can a wearable helmet treat depression at home?
- Could a 10-Week online course lift student depression and anxiety?
- Rewiring the mind after trauma: a new therapy aims to change how we process painful events